Quote:Trump’s Numbers Continue To Tank As 60% Of Americans Don’t Think He’s ‘Level-Headed’
By Sean Colarossi on Tue, Feb 7th, 2017 at 7:49 pm
Overall, the poll reflects a resounding rejection of Trump as a person and the agenda he has worked to implement over the course of his first several weeks in office.
It’s been less than three weeks since Donald Trump took the oath of office, and the American people are starting to question whether the new president is even sane enough to hold a job.
According to a new Quinnipiac University poll, a whopping 60 percent of registered voters say that Trump is not “level-headed.” Just a dismal 35 percent of the survey’s respondents say that he is.
This is no surprise given what Trump has managed to do over the first several weeks of his presidency, from lying about crowd sizes and wreaking havoc on American airports to threatening war with two countries and making a deadly and ill-formed foreign policy decision.
Quinnipiac’s finding is just one in a series of devastating numbers showing that a majority of the American people don’t think the president has positive leadership traits.
Some other findings that don’t bode well for Trump:
•54 percent say he is not honest
•50 percent say he doesn’t have good leadership skills
•52 percent say that he doesn’t care about the average American
•58 percent say that he does not share their values
On the policies Trump has implemented during his short time in the White House, the numbers – stunningly – are often even worse for the president.
More from Quinnipiac:
American voters oppose 51 – 46 percent President Donald Trump’s order suspending for 90 days all travel to the U.S. from seven nations, according to a Quinnipiac University national poll released today.
Voters oppose 60 – 37 percent President Trump’s order suspending immigration of all refugees from any nation to the U.S. for 120 days, the independent Quinnipiac (KWIN-uh-pe-ack) University Poll finds.
Voters also oppose 70 – 26 percent Trump’s order suspending indefinitely all immigration of Syrian refugees to the U.S.
Overall, the poll reflects a resounding rejection of Trump as a person and the agenda he has worked to implement over the course of his first several weeks – a time when presidents typically have their most favorable ratings.
If this is Trump’s ceiling of support, then he’s in for a tough four years – and, potentially, an even tougher re-election fight, if we manage to survive his first term.
You've 'cherry-picked' a poll. The majority of polls show
Top 10 Most Recent News Articles
Mazu Culture Forum Unveils New Initiatives in China
A Cultural Tapestry Unfurls in Putian Picture this: a kaleidoscope of cultures and ideas unraveling in the coastal city of Putian. The 11th Global Mazu Culture Forum kicks off on October 31, bringing together minds—both fresh and seasoned—from an impressive array of 47 countries and regions. It's more than a forum; it's a vibrant crossroads of innovation, tradition,...
Continue Reading
Foxconn Spotlights AI Advancements at Tech Day 2026
Foxconn's Bold Step into AI Infrastructure Foxconn, the tech giant that most folks recognize for its sheer prowess in electronics manufacturing, isn't just idling on past laurels. During the 7th annual Hon Hai Tech Day 2026, it was a showcase of fireworks that left attendees buzzing about the future of AI infrastructure and beyond. And when Foxconn says it's transforming,...
Continue Reading
Haunted Attraction Insights from the Queen of Haunts
Admit it—everyone's got that one fear that sends shivers down their spine. Whether it's the slithering scales of a snake or the manic laughter of a clown, those phobias are what make haunted attractions such a hit for thrillseekers across the country. Amber Arnett-Bequeaith, the so-called Queen of Haunts, knows a thing or two about turning those fears into unforgettable...
Continue Reading
European Doctors Explore Chinese Aesthetic Innovations
Pioneering Exchange in Regenerative Aesthetics Ever seen European doctors flocking to China to learn about beauty techniques? That's the scene as aphranel®, the brainchild of MOYOM Biotech, ushers in a week-long clinical exchange under 'The Norns' Weave.' The whole deal aims to unravel how Chinese practices could shape Europe's aesthetic landscape. Yep, it's all about...
Continue Reading
Gooru AI Unveils Platform to Scale Human Expertise
A New Wave of AI-Powered Solutions Hot off the press, Gooru AI's recent shindig in the heart of Dallas aimed to showcase something they call 'Digital Goorus.' Now that might sound like a newage tech gimmick but peel back the layers and you find an ambitious attempt to let folks spread their smarts without having to be everywhere all at once. Imagine being able to crack...
Continue Reading
Nanoscope Therapeutics Aims for Eye-Catching Advances
Gearing Up for a Boston Showcase Nanoscope's High-Stakes Boston Rendezvous In a move set to grab some serious eyeballs, Nanoscope Therapeutics is geared up to strut their stuff at Advanced Therapies USA 2026 in Boston. Scheduled for November 4–5 at the Hynes Convention Center, the event isn't just another pitstop—it's a billboard for what these guys have cooking. With...
Continue Reading
Okta Joins S&P 500 Amidst Major Index Shuffles
Okta Leaps to S&P 500: A Power Play You blink for a second, and boom, Okta's sitting at the big kids' table—the S&P 500. You know how rare that move is? It’s like snagging an invite to the party everyone wants to attend. Swapping out Kenvue Inc. (NYSE: KVUE), which Kimberly-Clark (NASD: KMB) is scooping up, Okta's maneuver signifies a hefty endorsement of its growth...
Continue Reading
MediaGo Wins Big in France with Optimized Strategies
MediaGo's Winning Edge in Advertising Shake the dust off your boots and get ready for a tale of triumph straight out of San Francisco. MediaGo, the top dog in global intelligent advertising platforms, just added a couple of shiny awards to its trophy case thanks to the prestigious Les Cas d'OR 2026 in France. And let me tell ya, these wins aren't just about some pretty...
Continue Reading
Lecanemab's New Data: What Investors Should Monitor
Lecanemab: A Bold Step in Alzheimer's Treatment? Investors eyeing the biotech sector should pay close attention to the upcoming CTAD conference in 2026, where BioArctic AB's partner, Eisai, is set to present fresh data on lecanemab (Leqembi®). This isn't just another pharma front-page story—this is about potential breakthroughs in Alzheimer's treatment that's caught...
Continue Reading
Fintech Shake-Up: OPay's $4B NYSE IPO Arrival
It's a big day on Wall Street as OPay dives into the NYSE with a hefty market cap of over $4 billion, signaling a major moment for the fintech arena. Oh, how times are shifting! Today marks the debut of OPay under the ticker 'OPAY,' and let me tell you, there's a buzz in the air that could quicken any seasoned trader's pulse. OPay's Big Day: A New Era of Fintech Their...
Continue ReadingTop 5 Most Recently Viewed Articles
Exploring Consumer Product Risks: Insights from Legal Experts
Investigation into Defective Consumer Products The Law Offices of Jason Turchin is currently investigating various claims related to defective consumer products that can potentially harm individuals. These products include commonly used items such as space heaters and HVAC systems, as well as kitchen equipment like coffee makers and pressure cookers. Each of these items...
Continue Reading
Nauticos Takes Bold Steps Toward Uncovering Earhart's Mystery
Nauticos Aims to Solve a Historic Mystery Nauticos, a leader in deep-sea exploration and historical research, has announced an exciting new expedition to locate Amelia Earhart's Lockheed Electra. This groundbreaking mission is fueled by proprietary data that pinpoints the likely resting place of the iconic aircraft. The research advances our understanding of where Earhart...
Continue Reading
Equitable Bank Achieves Historic $300 Million Deposit Note Success
Equitable Bank Closes Impressive $300 Million Deposit Note Issuance Equitable Bank, Canada's Challenger Bank™, has successfully closed a monumental $300 million floating rate deposit note issuance. This remarkable achievement marks the tightest spread on record for deposit notes of a similar term issued by the bank. The overwhelming response from investors demonstrates...
Continue Reading
Exploring the Long-Term Gains of Sprouts Farmers Market Stock
Understanding the Growth of Sprouts Farmers Market Stock Over the last decade, Sprouts Farmers Market (NASDAQ: SFM) has demonstrated remarkable growth, consistently surpassing market returns by an impressive 3.05% annually. With average annual returns reaching 14.93%, this company's performance is a topic of great interest among investors. Initial Investment Insights...
Continue Reading
Anticipating Royalty Pharma's First Quarter 2025 Financial Results
Upcoming Financial Results Announcement Royalty Pharma plc (Nasdaq: RPRX) is gearing up to share its financial journey for the first quarter of 2025 on May 8, 2025. As one of the largest buyers of biopharmaceutical royalties, the firm is set to unveil its latest financial results early in the day, prior to the opening of U.S. markets. This announcement will give investors...
Continue Reading